Targeted Therapies in the Treatment of Uterine Serous Carcinoma

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;70:7–33.

Article  Google Scholar 

Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10.

Article  CAS  PubMed  Google Scholar 

Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control. 2010;21:1851.

Article  PubMed  PubMed Central  Google Scholar 

Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463.

Article  PubMed  Google Scholar 

Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011;54:278.

Article  PubMed  Google Scholar 

Kosary C. Cancer of the corpus uterus. In: Uterus SEER Surviv Monogr Cancer Surviv Adults US SEER Program 1988-2001 1988-2001 NCI SEER Program Natl Cancer Inst. Bethesda MD; 2007.

Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(20):4048–53. https://doi.org/10.1200/JCO.2001.19.20.4048.

Article  CAS  Google Scholar 

Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. https://doi.org/10.1038/nature12113.

Article  CAS  Google Scholar 

Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123(802):13. https://doi.org/10.1002/cncr.30496.

Article  CAS  Google Scholar 

Talhouk A, Derocher H, Schmidt P, et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res. 2019;25:2537–48. https://doi.org/10.1158/1078-0432.CCR-18-3241.

Article  CAS  PubMed  Google Scholar 

Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.

Article  CAS  PubMed  Google Scholar 

Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A. 2013;110:2916–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rottman D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Mod Path. 2020 Jan;33(1):118–27.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

Article  CAS  PubMed  Google Scholar 

• Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplaitn-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2-/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26(15):3928–35 Randomized trial showing increased PFS and OS with addition of trastuzumab to carboplatin/paclitaxel in patients with advanced HER2/neu-positive USC.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-uterine neoplasms. Version 4.2019. 2019.

Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Target. Oncol. 2017;12:719–39. https://doi.org/10.1007/s11523-017-0535-0.

Article  PubMed  Google Scholar 

Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br. J. Cancer. 2017;117:1736–42. https://doi.org/10.1038/bjc.2017.367.

Article  CAS  PubMed  PubMed Central  Google Scholar 

English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Med. 2014;3(5):1256–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, et al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Onol. 147(1):145–52.

Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, et al. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2/Neu expression. Mol Cancer Ther. 2016;15:1900–9.

Article  CAS  PubMed  Google Scholar 

Krop IE, Kim S-B, González-Martín A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:689–9.

•• Tymon-Rosario J, Bonazzoli E. Bellone Stefania, et al. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecol Oncol. 2021;163(2):334–41. https://doi.org/10.1016/j.ygyno.2021.08.014 Describes a novel antibody-drug conjugate that is highly selective and toxic to HER2/neu-overexpressing USC tumors both in vitro and in vivo.

Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol. 2015;26:2034–43.

Article  CAS  PubMed  Google Scholar 

Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, et al. IMGN853, a folate receptor-α (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol Cancer Ther. 2015;14:1605–13.

Article  CAS  PubMed  Google Scholar 

Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, et al. In vitro and in vivo activity of IMGN852, an antibody-drug conjugate targeting folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers. Mol Cancer Ther. 2018 May;17(5):1003–11.

Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010;46:944–53. https://doi.org/10.1016/j.ejca.2009.12.019.

Article  CAS  PubMed  Google Scholar 

Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222–33. https://doi.org/10.1038/onc.2012.36.

Article  CAS  PubMed  Google Scholar 

Starodub AN, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin. Cancer Res. 2015;21:3870–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, et al. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecol Oncol. 2020;156(2):430–8 Describes a novel antibody-drug conjugate with significant activity in Trop-2-overexpressing USC tumors both in vitro and in vivo.

Article  CAS  PubMed  Google Scholar 

Segovia-Mendoza M, Gonzalez-Gonzalez ME, Barrera D, Diaz L, Garcia-Becerra R. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res. 2015;5(9):2531–61.

CAS  PubMed  PubMed Central  Google Scholar 

Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Br J Cancer. 2014;111(9):1750–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol. 2014;135(1):142–8.

Article  CAS  PubMed  Google Scholar 

Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. Tumour Biol. 2015;36(7):5505–13.

Article  CAS  PubMed  Google Scholar 

Santin AD. A phase II evaluation of afatinibin patients with persistent or recurrent HER2-positive uterine serous carcinoma (afatinib). NCT02491099. ClinicalTrials.gov: NIH.Available: https://clinicaltrials.gov/ct2/show/NCT02491099

•• Liu JF, Xiong N, Campos SM, et al. Phase II study of the Wee1 inhibitor adavosertib in recurrent uterine serous carcinoma. J Clin Oncol. 2021;39:JCO2003167. https://doi.org/10.1200/JCO.20.03167 Phase II study that demonstrated activity of selective oral inhibitor of Wee1 kinase in recurrent USC.

Article  CAS  Google Scholar 

de Jonge MM, Auguste A, van Wijk LM, et al. Frequent homologous recombination deficiency in high-grade endometrial carcinomas. Clin Cancer Res. 2019;25:1087–97. https://doi.org/10.1158/1078-0432.CCR-18-1443.

Article  PubMed  Google Scholar 

•• Yadav G, Roque DM, Bellone S, et al. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecol Oncol. 2022 Aug;166(2):351–7. https://doi.org/10.1016/j.ygyno.2022.05.021 Demonstrated synergistic activity of olaparib and neratinib against primary HER2/neu-positive USC.

Frimer M. Trial of maintenance with niraparib- uterine serous carcinoma ClinicalTrials.gov: NIH.Available: https://clinicaltrials.gov/ct2/show/NCT04080284

Herzog TJ, Arguello D, Reddy SK, et al. PD-1, PD-L1 expression in 1599 gynecological cancers: implications for immunotherapy. Gynecol Oncol. 2015;137:204–5. https://doi.org/10.1016/j.ygyno.2015.01.514.

Article  Google Scholar 

•• Cusimano MC, Vicus D, Pulman K, et al. Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging. JAMA Surg. 2021;156:157–64. https://doi.org/10.1001/jamasurg.2020.5060 Prospective cohort study showing diagnostic accuracy of sentinel lymph node biopsy in patients with high-grade endometrial cancer.

Article  PubMed  Google Scholar 

•• Makker V. Abstract 11512: A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician’s choice in patients with advanced endometrial cancer. Society of Gynecol Oncol Annual Meeting. 2021; Phase III randomized trial demonstrating improved PFS and OS with lenvatinib and pembrolizumab vs. chemotherapy.

•• Myers AP, Konstantinopoulos PA, Barry WT, et al. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020;147:413–22. https://doi.org/10.1002/ijc.32783 Phase II study demonstrating improved PFS in patients with recurrent USC with AKT inhibitor.

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif